Compare SUI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUI | UTHR |
|---|---|---|
| Founded | 1975 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 20.3B |
| IPO Year | 1993 | 1999 |
| Metric | SUI | UTHR |
|---|---|---|
| Price | $121.75 | $493.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $138.33 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 606.2K | 423.0K |
| Earning Date | 10-29-2025 | 10-29-2025 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 324.78 | 16.08 |
| EPS | 7.94 | ★ 26.38 |
| Revenue | ★ $3,236,900,000.00 | $3,128,400,000.00 |
| Revenue This Year | N/A | $13.64 |
| Revenue Next Year | $5.37 | $5.78 |
| P/E Ratio | ★ $15.31 | $18.73 |
| Revenue Growth | ★ 32.39 | 13.50 |
| 52 Week Low | $109.22 | $266.98 |
| 52 Week High | $137.77 | $496.73 |
| Indicator | SUI | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 65.89 |
| Support Level | $122.13 | $474.59 |
| Resistance Level | $125.45 | $489.99 |
| Average True Range (ATR) | 2.37 | 10.16 |
| MACD | -0.70 | -0.69 |
| Stochastic Oscillator | 7.38 | 91.64 |
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.